Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Federici

Showing results (21-30 of 215) with videos related to

Pageof 22
Sort By:
Metabolism: Clinical and Experimental|November 21, 2018
Metabolically healthy versus metabolically unhealthy obesityCarla Iacobini, Giuseppe Pugliese, Claudia Blasetti Fantauzzi, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|November 24, 2019
Osteoprotegerin in diabetic osteopathyAlessia Valentini, Maria A Cianfarani, Massimo Federici, et al.
Scientific Reports|July 29, 2017
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinomaViviana Casagrande, Alessandro Mauriello, Simone Bischetti, et al.
Frontiers in Endocrinology|February 5, 2024
TIMP3 overexpression in myeloid lineage alleviates pancreatic damage and confers resistance to the development of type 1 diabetes in the MLDS -induced modelViviana Casagrande, Stefano Menini, Chiara InternĂ², et al.
Clinical and Translational Medicine|February 26, 2021
Restoration of renal TIMP3 levels via genetics and pharmacological approach prevents experimental diabetic nephropathyViviana Casagrande, Giulia Iuliani, Stefano Menini, et al.
Clinical Interventions in Aging|February 24, 2017
Low FT3: a possible marker of frailty in the elderlyAldo Bertoli, Alessia Valentini, Maria Assunta Cianfarani, et al.
Acta Diabetologica|June 26, 2013
Regulation of TIMP3 in diabetic nephropathy: a role for microRNAsLoredana Fiorentino, Michele Cavalera, Maria Mavilio, et al.
Diabetes Research and Clinical Practice|October 16, 2024
Role of MASLD in CVD: A review of emerging treatment optionsRocco Mollace, Susanna Longo, Matteo Nardin, et al.
Journal of the American Geriatrics Society|April 20, 2010
Adiponectin isoforms in elderly patients with or without coronary artery diseaseStefano Rizza, Fabrizio Gigli, Angelica Galli, et al.
The International Journal of Biochemistry & Cell Biology|November 26, 2019
Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target?Rossella Menghini, Viviana Casagrande, Giulia Iuliani, et al.
Pageof 22

Showing results (21-30 of 215) with videos related to

Sort By:
Pageof 22
Metabolism: Clinical and Experimental|November 21, 2018
Metabolically healthy versus metabolically unhealthy obesityCarla Iacobini, Giuseppe Pugliese, Claudia Blasetti Fantauzzi, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|November 24, 2019
Osteoprotegerin in diabetic osteopathyAlessia Valentini, Maria A Cianfarani, Massimo Federici, et al.
Scientific Reports|July 29, 2017
Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinomaViviana Casagrande, Alessandro Mauriello, Simone Bischetti, et al.
Frontiers in Endocrinology|February 5, 2024
TIMP3 overexpression in myeloid lineage alleviates pancreatic damage and confers resistance to the development of type 1 diabetes in the MLDS -induced modelViviana Casagrande, Stefano Menini, Chiara InternĂ², et al.
Clinical and Translational Medicine|February 26, 2021
Restoration of renal TIMP3 levels via genetics and pharmacological approach prevents experimental diabetic nephropathyViviana Casagrande, Giulia Iuliani, Stefano Menini, et al.
Clinical Interventions in Aging|February 24, 2017
Low FT3: a possible marker of frailty in the elderlyAldo Bertoli, Alessia Valentini, Maria Assunta Cianfarani, et al.
Acta Diabetologica|June 26, 2013
Regulation of TIMP3 in diabetic nephropathy: a role for microRNAsLoredana Fiorentino, Michele Cavalera, Maria Mavilio, et al.
Diabetes Research and Clinical Practice|October 16, 2024
Role of MASLD in CVD: A review of emerging treatment optionsRocco Mollace, Susanna Longo, Matteo Nardin, et al.
Journal of the American Geriatrics Society|April 20, 2010
Adiponectin isoforms in elderly patients with or without coronary artery diseaseStefano Rizza, Fabrizio Gigli, Angelica Galli, et al.
The International Journal of Biochemistry & Cell Biology|November 26, 2019
Metabolic aspects of cardiovascular diseases: Is FoxO1 a player or a target?Rossella Menghini, Viviana Casagrande, Giulia Iuliani, et al.
Pageof 22